On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp/MVC to apply next-generation sequencing to MVC’s new multivalent enterovirus vaccine program. On its own, the deal is small. But it shows Charles River finding fresh uses for the sequencing technology it picked up through an earlier acquisition, and it lands just two weeks after a mixed second quarter that raised guidance but posted a GAAP loss. Investors are left weighing two different stories at once.
Sequencing Its Way Into Vaccines
Under the collaboration, Charles River will characterize and validate the virus seed bank behind MVC’s next-generation enterovirus vaccine, using Next-Generation Sequencing to support the chemistry, manufacturing, and controls work needed to satisfy global regulators. MVC already has a commercialized enterovirus vaccine approved in Taiwan and Vietnam, so this is a company with a track record picking Charles River as its partner for the harder next step.
The two companies say they will also explore other vaccine programs together, which points to more than a one-off contract. That NGS work traces back to Charles River’s acquisition of Pathoquest, a specialist in sequencing-based testing for biopharmaceuticals, and the same capability turned up again in the second quarter, when Charles River struck a testing collaboration with Arovella Therapeutics on cancer treatments and joined Eli Lilly’s TuneLab platform to support drug discovery.
Layered on an AI-enabled digital pathology tool meant to speed up study turnaround, the DSA segment posted its highest net book-to-bill in nearly four years, prompting management to raise both organic revenue and non-GAAP earnings guidance for 2026. The Manufacturing segment’s non-GAAP operating margin climbed to 37.8% from 32.8% a year earlier, and Charles River kept buying back stock, spending $300 million on 1.7 million shares through the first half of the year, with $700 million left on its authorization.
A Quarter Of Mixed Signals
The second quarter’s headline numbers were not as clean. Revenue fell 2.7% year over year to $1.00 billion, and organic growth of just 0.1% was still the best the company has managed since 2023, a sign of how sluggish the prior stretch had been. The Research Models and Services segment kept sliding, with revenue down 1.8% as demand for small research models weakened in North America even as China picked up some slack. Charles River posted a GAAP loss of $0.03 per share, versus a profit of $1.06 a year ago, almost entirely because of a $63.7 million loss tied to divesting its CDMO and Cell Solutions businesses along with certain European Discovery Services sites.
Even stripping out those one-time items, non-GAAP earnings per share fell 3.2% to $3.02, as higher study-related costs in DSA and rising corporate expenses pushed the non-GAAP operating margin down to 20.5% from 22.1%. Management is raising its non-GAAP guidance for the year. Still, it cut GAAP earnings per share guidance to reflect the divestiture losses, a reminder that the portfolio cleanup carries real accounting costs even as it clears the way for the businesses Charles River wants to grow.
What The Numbers Whisper
The number of hedge funds holding Charles River rose to 47 from 43 the prior quarter, a modest pickup in institutional interest. Short sellers have not backed off, with 6.14% of the float sold short, enough to reflect a real bear camp rather than passing skepticism. The stock trades at a forward P/E of 22.47 as of September 21, a multiple that assumes earnings growth resumes rather than one that prices in more quarters like the one just reported. Rising fund ownership alongside meaningful short interest suggests the market is still arguing with itself over which of Charles River’s two stories will win out.
Two Stories, One Stock
Charles River is trying to prove it can extend its testing expertise into new corners of drug and vaccine development while trimming the businesses that no longer fit. The vaccine collaboration and the guidance raise say that strategy is gaining traction. The GAAP loss and the shrinking core segments say the transition still has real costs to absorb. For the growth story to hold, the DSA rebound and the new sequencing partnerships need to keep compounding into next year. For the skeptics to be right, the divestitures need to keep generating charges large enough to offset whatever operational progress shows up underneath.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
